Interim data from a Phase 1 trial showed 50% objective response rate in patients receiving PLN-101095 with pembrolizumab at the highest dose tested (1000 mg BID), with confirmed partial responses across multiple tumor types including NSCLC, melanoma, and cholangiocarcinoma.
Pliant Therapeutics has temporarily suspended enrollment and dosing in its Phase IIb/III BEACON-IPF trial of Bexotegrast following recommendations from the independent Data Safety Monitoring Board.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.